Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
Avidity Biosciences (Nasdaq: RNA) has announced an upcoming investor and analyst event (Volume 11) scheduled for November 12, 2024, at 8:00 a.m. ET. The company will unveil new development candidates from its precision cardiology portfolio and showcase next-generation technology innovations.
Additionally, Avidity will present a poster on their lead precision cardiology candidate at the American Heart Association (AHA) Scientific Sessions 2024 on November 16, 2024, at 11:40 a.m. CT in Chicago. The presentation will focus on a novel precision cardiology treatment for PRKAG2 Cardiomyopathy, a subset of patients with Wolff-Parkinson-White Syndrome.
Avidity Biosciences (Nasdaq: RNA) ha annunciato un imminente evento per investitori e analisti (Volume 11) programmato per 12 novembre 2024, alle 8:00 a.m. ET. L'azienda presenterà nuovi candidati allo sviluppo provenienti dal suo portafoglio di cardiologia di precisione e metterà in luce innovazioni tecnologiche di nuova generazione.
Inoltre, Avidity presenterà un poster sul proprio candidato principale in cardiologia di precisione durante le Sessioni Scientifiche 2024 dell'American Heart Association (AHA), il 16 novembre 2024, alle 11:40 a.m. CT a Chicago. La presentazione si concentrerà su un nuovo trattamento di cardiologia di precisione per la cardiomiopatia PRKAG2, una sottocategoria di pazienti con sindrome di Wolff-Parkinson-White.
Avidity Biosciences (Nasdaq: RNA) ha anunciado un próximo evento para inversores y analistas (Volumen 11) programado para 12 de noviembre de 2024, a las 8:00 a.m. ET. La compañía revelará nuevos candidatos en desarrollo de su cartera de cardiología de precisión y mostrará innovaciones tecnológicas de última generación.
Adicionalmente, Avidity presentará un póster sobre su candidato principal en cardiología de precisión en las Sesiones Científicas 2024 de la American Heart Association (AHA) el 16 de noviembre de 2024, a las 11:40 a.m. CT en Chicago. La presentación se centrará en un nuevo tratamiento de cardiología de precisión para la cardiomiopatía PRKAG2, un subconjunto de pacientes con síndrome de Wolff-Parkinson-White.
아비디티 바이오사이언스(Avidity Biosciences) (Nasdaq: RNA)는 2024년 11월 12일 오전 8시(ET)에 예정된 투자자 및 분석가 행사(11권)를 발표했습니다. 이 회사는 정밀 심장병 포트폴리오의 새로운 개발 후보를 공개하고 차세대 기술 혁신을 선보일 것입니다.
또한 아비디티는 미국심장협회(AHA) 2024년 과학 세션에서 2024년 11월 16일 오전 11시 40분(CT) 시카고에서 자사의 주요 정밀 심장병 후보에 대한 포스터를 발표할 것입니다. 발표는 PRKAG2 심근병증에 대한 새로운 정밀 심장병 치료법에 초점을 맞출 것이며, 이는 울프-파킨슨-화이트 증후군 환자의 하위 집합입니다.
Avidity Biosciences (Nasdaq: RNA) a annoncé un prochain événement pour investisseurs et analystes (Volume 11) prévu pour le 12 novembre 2024 à 8h00 ET. L'entreprise dévoilera de nouveaux candidats au développement de son portefeuille de cardiologie de précision et présentera des innovations technologiques de nouvelle génération.
De plus, Avidity présentera un poster sur son principal candidat en cardiologie de précision lors des Sessions Scientifiques 2024 de l'American Heart Association (AHA) le 16 novembre 2024 à 11h40 CT à Chicago. La présentation se concentrera sur un nouveau traitement de cardiologie de précision pour la cardiomyopathie PRKAG2, un sous-ensemble de patients atteints du syndrome de Wolff-Parkinson-White.
Avidity Biosciences (Nasdaq: RNA) hat eine bevorstehende Investoren- und Analystenveranstaltung (Band 11) angekündigt, die für 12. November 2024 um 8:00 Uhr ET geplant ist. Das Unternehmen wird neue Entwicklungskandidaten aus seinem Portfolio für präzise Kardiologie vorstellen und Innovationen der nächsten Generation präsentieren.
Zusätzlich wird Avidity ein Poster zu ihrem führenden Kandidaten in der präzisen Kardiologie bei den Wissenschaftlichen Sitzungen 2024 der American Heart Association (AHA) am 16. November 2024 um 11:40 Uhr CT in Chicago präsentieren. Die Präsentation wird sich auf eine neuartige Behandlung der präzisen Kardiologie für PRKAG2-Kardiomyopathie konzentrieren, eine Untergruppe von Patienten mit Wolff-Parkinson-White-Syndrom.
- None.
- None.
Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18, 2024
Volume 11 of investor and analyst event series will be available via webcast November 12, 2024, at 8:00 a.m. ET
Video Webcast Information
The company is hosting Volume 11 of its investor and analyst event series on November 12, 2024, beginning at 8:00 a.m. ET. The virtual event will be available via a live video webcast and can be accessed here or from the "Events and Presentations" page in the "Investors" section of Avidity's website. A replay of the webcast will be archived on Avidity's website following the event.
Avidity will be presenting a poster on a lead precision cardiology candidate at the American Heart Association (AHA) Scientific Sessions 2024 on November 16, 2024, at 11:40 a.m. CT in
POSTER PRESENTATION
November 16, 2024: 11:40 a.m. - 11:45 a.m. CT
- Novel Precision Cardiology Treatment for PRKAG2 Cardiomyopathy, a Subset of Patients with Wolff-Parkinson-White Syndrome
The poster will be available on the publications page of Avidity's website at https://www.aviditybiosciences.com.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.
Investor Contact:
Mike MacLean
(619) 837-5014
investors@aviditybio.com
Media Contact:
Navjot Rai
(619) 837-5016
media@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-host-investor-and-analyst-event-focused-on-precision-cardiology-candidates-and-first-look-at-next-generation-technology-innovations-on-november-12-2024-302292234.html
SOURCE Avidity Biosciences, Inc.
FAQ
When is Avidity Biosciences (RNA) hosting its Volume 11 investor event?
What will Avidity Biosciences (RNA) present at the AHA Scientific Sessions 2024?
What new developments will Avidity Biosciences (RNA) share at their November 2024 investor event?
